These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33831049)

  • 21. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
    Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
    Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 10-Valent pneumococcal non-typeable
    Oguoma VM; Wilson N; Mulholland K; Santosham M; Torzillo P; McIntyre P; Smith-Vaughan H; Balloch A; Chatfield M; Lehmann D; Binks MJ; Chang A; Carapetis J; Krause V; Andrews R; Snelling T; Licciardi P; Morris P; Leach AJ
    BMJ Open; 2020 May; 10(5):e033511. PubMed ID: 32448790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.
    Gomez JA; Tirado JC; Navarro Rojas AA; Castrejon Alba MM; Topachevskyi O
    BMC Public Health; 2013 Oct; 13():1025. PubMed ID: 24171921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Serotype Prevalence of Pneumococci Isolated from Middle Ear, Lower Respiratory Tract and Invasive Disease Prior to Vaccination in Iceland.
    Hjálmarsdóttir MÁ; Quirk SJ; Haraldsson G; Erlendsdóttir H; Haraldsson Á; Kristinsson KG
    PLoS One; 2017; 12(1):e0169210. PubMed ID: 28125588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction of Streptococcus pneumoniae in upper respiratory tract cultures and a decreased incidence of related acute otitis media following introduction of childhood pneumococcal conjugate vaccines in a Swedish county.
    Littorin N; Ahl J; Uddén F; Resman F; Riesbeck K
    BMC Infect Dis; 2016 Aug; 16(1):407. PubMed ID: 27514843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model.
    Bakır M; Türel O; Topachevskyi O
    BMC Health Serv Res; 2012 Nov; 12():386. PubMed ID: 23137037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial.
    Palmu AA; Jokinen J; Nieminen H; Rinta-Kokko H; Ruokokoski E; Puumalainen T; Moreira M; Schuerman L; Borys D; Kilpi TM
    Vaccine; 2018 Mar; 36(14):1816-1822. PubMed ID: 29503110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
    Tregnaghi MW; Sáez-Llorens X; López P; Abate H; Smith E; Pósleman A; Calvo A; Wong D; Cortes-Barbosa C; Ceballos A; Tregnaghi M; Sierra A; Rodriguez M; Troitiño M; Carabajal C; Falaschi A; Leandro A; Castrejón MM; Lepetic A; Lommel P; Hausdorff WP; Borys D; Ruiz Guiñazú J; Ortega-Barría E; Yarzábal JP; Schuerman L;
    PLoS Med; 2014 Jun; 11(6):e1001657. PubMed ID: 24892763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.
    Robberstad B; Frostad CR; Akselsen PE; Kværner KJ; Berstad AK
    Vaccine; 2011 Nov; 29(47):8564-74. PubMed ID: 21945264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness Comparison of Pneumococcal Conjugate Vaccines in Turkish Children.
    Marijam A; Olbrecht J; Ozakay A; Eken V; Meszaros K
    Value Health Reg Issues; 2019 Sep; 19():34-44. PubMed ID: 30776766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.
    Weil-Olivier C; van der Linden M; de Schutter I; Dagan R; Mantovani L
    BMC Infect Dis; 2012 Sep; 12():207. PubMed ID: 22954038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial.
    Palmu AA; Jokinen J; Nieminen H; Syrjänen R; Ruokokoski E; Puumalainen T; Moreira M; Schuerman L; Borys D; Kilpi TM
    Lancet Respir Med; 2014 Sep; 2(9):717-27. PubMed ID: 25127244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban national immunization programme.
    García Fariñas A; Linares-Pérez N; Clark A; Toledo-Romaní ME; Omeiri NE; Marrero Araújo MC; Gonzálvez Luis IP; Toraño Peraza G; Reyes Jiménez A; López Ambrón L;
    Int J Infect Dis; 2020 Aug; 97():182-189. PubMed ID: 32474199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
    Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
    PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.
    Blank PR; Szucs TD
    Vaccine; 2012 Jun; 30(28):4267-75. PubMed ID: 22521287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.
    Strutton DR; Farkouh RA; Earnshaw SR; Hwang S; Theidel U; Kontodimas S; Klok R; Papanicolaou S
    J Infect; 2012 Jan; 64(1):54-67. PubMed ID: 22085813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience.
    Mrkvan T; Pelton SI; Ruiz-Guiñazú J; Palmu AA; Borys D
    Expert Rev Vaccines; 2018 Sep; 17(9):797-818. PubMed ID: 30185083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pneumococcal vaccine impact on otitis media microbiology: A New Zealand cohort study before and after the introduction of PHiD-CV10 vaccine.
    Best EJ; Walls T; Souter M; Neeff M; Anderson T; Salkeld L; Ahmad Z; Mahadevan M; Walker C; Murdoch D; Mills N
    Vaccine; 2016 Jul; 34(33):3840-7. PubMed ID: 27265454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions.
    Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
    Hum Vaccin Immunother; 2022 Dec; 18(1):1942712. PubMed ID: 34319865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.